title: Sulfanegen sodium treatment in a rabbit model of sub-lethal cyanide toxicity.
abstract: The aim of this study is to investigate the ability of intramuscular and intravenous sulfanegen sodium treatment to reverse cyanide effects in a rabbit model as a potential treatment for mass casualty resulting from cyanide exposure. Cyanide poisoning is a serious chemical threat from accidental or intentional exposures. Current cyanide exposure treatments, including direct binding agents, methemoglobin donors, and sulfur donors, have several limitations. Non-rhodanese mediated sulfur transferase pathways, including 3-mercaptopyruvate sulfurtransferase (3-MPST) catalyze the transfer of sulfur from 3-MP to cyanide, forming pyruvate and less toxic thiocyanate. We developed a water-soluble 3-MP prodrug, 3-mercaptopyruvatedithiane (sulfanegen sodium), with the potential to provide a continuous supply of substrate for CN detoxification. In addition to developing a mass casualty cyanide reversal agent, methods are needed to rapidly and reliably diagnose and monitor cyanide poisoning and reversal. We use non-invasive technology, diffuse optical spectroscopy (DOS) and continuous wave near infrared spectroscopy (CWNIRS) to monitor physiologic changes associated with cyanide exposure and reversal. A total of 35 animals were studied. Sulfanegen sodium was shown to reverse the effects of cyanide exposure on oxyhemoglobin and deoxyhemoglobin rapidly, significantly faster than control animals when administered by intravenous or intramuscular routes. RBC cyanide levels also returned to normal faster following both intramuscular and intravenous sulfanegen sodium treatment than controls. These studies demonstrate the clinical potential for the novel approach of supplying substrate for non-rhodanese mediated sulfur transferase pathways for cyanide detoxification. DOS and CWNIRS demonstrated their usefulness in optimizing the dose of sulfanegen sodium treatment.
authors: Laser Microbeam and Medical Program, Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA 92612-1475, USA. mbrenner@uci.edu
authors: Matthew
authors: M
authors: Brenner
authors: Jae G
authors: JG
authors: Kim
authors: Jangwoen
authors: J
authors: Lee
authors: Sari B
authors: SB
authors: Mahon
authors: Daniel
authors: D
authors: Lemor
authors: Rebecca
authors: R
authors: Ahdout
authors: Gerry R
authors: GR
authors: Boss
authors: William
authors: W
authors: Blackledge
authors: Lauren
authors: L
authors: Jann
authors: Herbert T
authors: HT
authors: Nagasawa
authors: Steven E
authors: SE
authors: Patterson
mesh_terms: D000818:Animals; D003486:Cyanides / Q000037:antagonists & inhibitors / Q000633:toxicity*; D004195:Disease Models, Animal; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry* / Q000627:therapeutic use*; D011355:Prodrugs / Q000737:chemistry* / Q000627:therapeutic use*; D011817:Rabbits; D013466:Sulfurtransferases / Q000737:chemistry* / Q000627:therapeutic use*
chemical_list: C572639:2,5-dihydroxy-1,4-dithiane-2,5-dicarboxylic acid; D003486:Cyanides; D006573:Heterocyclic Compounds, 1-Ring; D011355:Prodrugs; D013466:Sulfurtransferases; C021550:3-mercaptopyruvate sulphurtransferase